Aurobindo Pharma Financial Results - Balance Sheet, Asset Details & Cash Flow

Aurobindo Pharma NSE

511.30 00.00 (1.04%) Profit Profit

Pharmaceuticals

To view real-time data of Aurobindo Pharma and trade with industry first features, Login or Open Free Demat Account.

Showing Financial Results

Share Price

Technical Analysis

Fundamental Analysis

Financial Results

Stock Performance

Peer Comparision

Financials:

Income Statement

as of March 2022

Financial Year	FY 2021-22	FY 2020-21	FY 2019-20	FY 2018-19	FY 2017-18
All Expenditure (Cr)	9,888.45	11,703.85	10,672.91	9,858.92	7,633.14
Operating Profit (Cr)	0.00	0.00	0.00	0.00	0.00
EBIDTA (Cr)	2,069.68	4,709.69	2,941.29	2,508.57	2,750.66
Profit Before Tax (Cr)	1,637.48	4,193.01	2,370.05	1,964.62	2,342.94
Tax (Cr)	182.77	1,080.10	493.17	434.89	530.17
Net Income (Cr)	11,958.13	16,413.54	13,614.20	12,367.49	10,383.80
EPS (Cr)	24.83	53.13	32.03	26.11	30.94
DPS (Cr)	0.00	0.00	0.00	0.00	0.00

Financial Quarterly	Dec-2022	Sept-2022	Jun-2022	Mar-2022	Dec-2021
All Expenditure (Cr)	2,959.04	2,729.76	2,544.66	2,454.91	2,407.14
Operating Profit (Cr)	13.79	55.48	51.83	9.34	8.62
EBIDTA (Cr)	19.83	19.83	19.83	19.83	19.83
Profit Before Tax (Cr)	404.49	223.76	170.07	739.50	242.46
Tax (Cr)	114.15	62.13	56.90	25.41	88.81
Net Income (Cr)	3,510.99	3,081.52	2,825.63	3,300.54	2,754.34
EPS (Cr)	5.10	2.81	2.08	13.69	4.09
DPS (Cr)	0.00	0.00	0.00	0.00	1.50

Financial Year	FY 2021-22	FY 2020-21	FY 2019-20	FY 2018-19	FY 2017-18
All Expenditure (Cr)	19,227.94	19,496.58	18,315.20	15,759.95	12,728.08
Operating Profit (Cr)	19.39	22.84	21.71	20.56	23.50
EBIDTA (Cr)	856.41	1,345.09	1,341.75	1,053.04	832.50
Profit Before Tax (Cr)	3,372.74	7,343.60	3,743.02	3,091.35	3,241.20
Tax (Cr)	725.63	2,009.77	899.35	726.85	818.27
Net Income (Cr)	23,075.19	29,135.18	23,392.24	20,397.12	17,050.67
EPS (Cr)	45.20	91.05	48.56	40.36	41.36
DPS (Cr)	0.00	0.00	0.00	0.00	0.00

Financial Quarterly	Dec-2022	Sept-2022	Jun-2022	Mar-2022	Dec-2021
All Expenditure (Cr)	5,453.31	4,949.81	5,303.41	5,001.84	4,993.04
Operating Profit (Cr)	19.16	65.72	59.08	14.03	12.79
EBIDTA (Cr)	19.83	19.83	19.83	19.83	19.83
Profit Before Tax (Cr)	680.11	523.36	678.99	593.63	793.78
Tax (Cr)	136.07	165.92	189.10	10.52	237.65
Net Income (Cr)	6,499.78	5,796.56	6,276.54	5,858.25	6,102.00
EPS (Cr)	8.38	6.99	8.88	9.84	10.32
DPS (Cr)	3.00	0.00	0.00	0.00	1.50

Balance Sheet

as of March 2022

Financial Year	FY 2021-22	FY 2020-21	FY 2019-20	FY 2018-19	FY 2017-18
Share Capital (Cr)	58.59	58.59	58.59	58.59	58.59
Reserves & Surplus (Cr)	17,058.75	15,866.02	12,993.91	11,292.03	9,923.99
Current Liabiltiies (Cr)	2,627.51	3,291.03	3,138.89	2,687.53	2,440.72
Other Liabilities (Cr)	5.03	0.00	42.68	22.64	33.60
Total Liabilities (Cr)	19,017.26	19,966.57	16,836.64	15,893.06	13,735.18

Financial Year	FY 2021-22	FY 2020-21	FY 2019-20	FY 2018-19	FY 2017-18
Fixed Assets	3,810.98	5,206.96	5,232.65	4,938.71	4,536.95
Current Assets	7,251.41	8,984.55	8,561.31	8,160.66	6,922.52
Other Assets	11,637.18	8,811.10	6,606.05	6,642.34	5,631.08
Total Assets	19,017.26	19,966.57	16,836.64	15,893.06	13,735.18

Financial Quarterly	FY Sept-2022	FY Mar-2022	FY Sept-2021	FY Mar-2021	FY Sept-2020
Share Capital (Cr)	58.59	58.59	58.59	58.59	58.59
Reserves & Surplus (Cr)	17,085.22	17,058.75	16,189.27	15,866.02	14,406.78
Current Liabiltiies (Cr)	47.38	103.36	107.64	111.00	129.54
Other Liabilities (Cr)	0.00	0.00	0.00	0.00	0.00
Total Liabilities (Cr)	21,079.57	19,254.29	19,955.95	20,399.95	18,186.21

Equities & Liabilities

Financial Year	FY 2021-22	FY 2020-21	FY 2019-20	FY 2018-19	FY 2017-18
Share Capital (Cr)	58.59	58.59	58.59	58.59	58.59
Reserves & Surplus (Cr)	24,517.39	21,871.28	16,766.08	13,832.19	11,621.83
Current Liabiltiies (Cr)	6,429.87	6,498.05	6,114.36	5,515.07	4,962.81
Other Liabilities (Cr)	212.91	250.71	162.19	80.16	66.43
Total Liabilities (Cr)	27,638.23	27,518.78	22,813.38	20,939.29	16,518.60

Assets

Financial Year	FY 2021-22	FY 2020-21	FY 2019-20	FY 2018-19	FY 2017-18
Fixed Assets	14,279.29	12,435.11	11,382.39	10,143.31	8,103.72
Current Assets	11,748.94	13,781.19	10,461.33	10,000.50	7,754.50
Other Assets	11,884.67	9,500.32	7,956.55	8,351.34	6,337.26
Total Assets	612.85	711.47	414.95	435.26	348.84

Financial Quarterly	FY Sept-2022	FY Mar-2021	FY Sept-2020	FY Sept-2018	FY Mar-2018
Share Capital (Cr)	58.59	58.59	58.59	58.59	58.59
Reserves & Surplus (Cr)	25,469.47	21,871.27	18,283.18	12,915.18	11,621.83
Current Liabiltiies (Cr)	6,345.53	5,690.50	5,927.20	5,156.34	4,448.34
Other Liabilities (Cr)	0.00	0.00	0.00	0.00	0.00
Total Liabilities (Cr)	30,607.25	27,991.55	24,208.17	18,836.67	16,455.92

Cash Flows

as of March 2022

Financial Year	FY 2021-22	FY 2020-21	FY 2019-20	FY 2018-19	FY 2017-18
Operating Activities (Cr)	5,016.48	3,329.05	4,381.28	1,650.97	1,954.52
Investing Activities (Cr)	-3,211.36	596.57	-1,562.86	-2,904.39	-1,926.76
Financing Activities (Cr)	-2,969.27	-1,364.94	-1,947.18	1,919.06	864.15
Others (Cr)	20.05	35.54	17.40	-9.14	-0.79
Net Cash Flow (Cr)	-1,164.15	2,560.68	871.24	665.64	891.91

Financial Year	FY 2021-22	FY 2020-21	FY 2019-20	FY 2018-19	FY 2017-18
Operating Activities (Cr)	3,726.71	2,994.53	2,201.38	529.89	922.40
Investing Activities (Cr)	-1,614.54	-2,650.24	-948.08	-1,300.54	-990.60
Financing Activities (Cr)	-2,447.54	-28.06	-1,254.65	599.40	439.69
Others (Cr)	47.23	-19.01	2.23	-6.44	2.33
Net Cash Flow (Cr)	-335.37	316.23	-1.35	-171.25	371.49

Aurobindo Pharma Financial Statements Overview

Aurobindo Pharma financial statements offers an overview of the company's Revenue, Income Statement, Balance Statement, Cash Flows and more. It helps to analyse the company's financial position and its revenue to profit trend. Aurobindo Pharma reported a Net Income of Rs. 23,075.19 and an Operating Profit of Rs. 19.39 in the . The Total Liabilities stood at Rs. 27,638.23 in the last year. The Earning Per Share (EPS) and Dividend Per Share (DPS) stood at Rs. 45.20 and Rs. 0.00 respectively. While, analysing Financial Statements of a company is crucial, it is equally important to look at the Share Price, Stock Performance, Fundamental Analysis, Technicals and Similar Stocks Comparision. It gives a sense of whether the company is growing, stable or deteriorating.